Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT). Detailed Description: Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
- 24 July 2024 - 1 mins read
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT). Detailed Description: Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
Related Clinical Trials
24 July 2024
1 mins read
A study to evaluate the effect of phenytoin or itraconazole on the circulating levels of IPN60130 in healthy adult participants
24 July 2024
1 mins read
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva...
24 July 2024
1 mins read
A study to assess whether adding maintenance cabozantinib (XL184) to best supportive care helps children, adolescents and young adults with osteosarcoma.
24 July 2024
2 mins read
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults
24 July 2024
2 mins read
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults
24 July 2024
1 mins read
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
24 July 2024
2 mins read
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
24 July 2024
2 mins read
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
24 July 2024
1 mins read
Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
24 July 2024
1 mins read